HTL0039732
Undisclosed
PreclinicalActive
Key Facts
About Nxera Pharma
Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| ASPEN Study Program | Insmed | Phase 3 |
| ARISE Study Program | Insmed | Phase 3 |
| MGL-2086 | Madrigal Pharmaceuticals | Phase 1 |
| Innovative Proprietary/Licensed Products | Laboratorios Farmaceuticos Rovi | Various |
| Undisclosed Partnered Program | Septerna | Discovery |
| Undisclosed Cell Therapy | Immix Biopharma | Pre-clinical |
| LYT-310 | PureTech Health | Preclinical |
| Bispecific (Undisclosed) | MacroGenics | Preclinical |
| Sec61 Portfolio Assets | Kezar Life Sciences | Preclinical |
| WTX-518 | Werewolf Therapeutics | Preclinical |
| WTX-712 | Werewolf Therapeutics | Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |